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In recent decades, there has been a recognition that the demand for preventative and
treatment services against mental health disorders and substance abuse far outstretches available
personnel and resources. The historically dwindling number of qualified mental health providers
and technicians has been problematic to the general population of the United States, but the
problem is even more profound for the adolescents. Substance Use Disorder (SUD) is a clinical
condition of dependence on substances/drugs and involves a triad of psychological dependence
(craving and procurement), physiologic dependence (withdrawal symptoms on discontinuation),
and tolerance (increasing dose to achieve the desired effect) (McPhee et al., 2019). Clinical
features of substance use disorder involve alteration in the brain, behaviors, and impulses
resulting in clinically significant physical, behavioral, and social dysfunctions (Edalati et al.,
2018). Depressive disorders (DD) mainly involve Major Depressive Disorder (MDD), a
condition characterized by clinically significant negative feelings, emotions, and thoughts
leading to periods of sadness and lack of interest in previously pleasurable activities (Bernaras, et
al., 2019). Both SUD and DD are preventable when appropriate resources are in place before
onset. Because prevention is not always possible, it is paramount for the early detection of both
SUD and DD to mitigate possible life-long sequelae of the effects of these conditions.
Adolescence is an age of increased independence, high-risk behaviors, and curiosity. It is
a period of major changes some of which can predispose DD and risk of SUD(LeMoult et al,
2020; Gobbi et al., 2019; Lu, 2019; Jordan & Andersen, 2017). Initiation of substance use is
more popular in adolescence through experimentation and buckling to peer pressure. Without
appropriate intervention, most adolescents maintain substance use onwards into adulthood. The
DD risk in adolescence involves a combination of factors such as physiologic, hormonal, and
physical changes as well as increased awareness of personal physique, need for friendships, and

the psycho-emotional burden of competing for and impressing potential romantic partners. There
is also the contribution of parents trying to tame risky adolescent behaviors which can at times be
countered by adolescents’ resistance as they demand increased autonomy.
Although substance abuse continues to be a major public health problem in the
adolescent population in the United States, the latest trends indicate that there are more
adolescents than ever before using substances, particularly marijuana (Weinberger et al., 2020).
Even though the adolescent usage rates for opioids, heroin, and prescription pain relievers has
steadily declined, marijuana and LSD use has peaked at an alarming rate in the same period and
the usage rates for alcohol, prescription stimulants, methamphetamine, and cocaine have not
improved (McCance-Katz, 2020). This occurred at a time of increasing rates of DD in the
population of under 50 years olds but with more significant increases in the adolescent age group
(McCance-Katz, 2020). Most recent depression rates stand above 15% for ages 12 - 25 years
with the prevalence significantly higher in females (McCance-Katz, 2020). The simultaneous
increases in SUD and DD, though shocking, are consistent with increasing evidence on the
cooccurrence of substance abuse and depression (Welsh et al, 2017; Johannessen et al 2017;
Keye et al, 2019). Therefore, SUD and DD cannot be treated in isolation due to their significant
cooccurrence as well the risk of each predisposing to the other.

The problem
The scope of preventative care in pediatrics regularly sidelines the significance of
substance abuse and depression in the overall wellbeing of pediatric patients. The Centers for
Disease Control and Prevention (CDC) regularly tracks data on the prevalence of SUD and DD
and the availability of treatment and therapy options for this population. As of 2019, the

treatment gaps for SUD and DD were 89.7% and 56.7% respectively (McCance-Katz, 2020),
consistent with historic dearth in the general mental health sector. Notably, these statistics
account only for diagnosed cases. In the case of SUD, most of the cases that receive intervention
are channeled through the justice system and not pediatric primary care (Belenko et al., 2017).
While these low intervention rates contribute to the increased prevalence of SUD and DD, they
are far from being the only problem. The latest statistics available indicate that the pediatric
screening rates using validated tools for SUD currently stand at 14% while those of DD are
currently at 34% (Harder et al., 2019; Harris et al., 2012). This indicates that in the combination
of factors that contribute to the generally high prevalence rate for these two conditions, a low
screening rate is a major contributor. The American Academy of Pediatrics (AAP) continues to
advocate for increased screening rates and early intervention against both conditions (Connors et
al., 2019) and this sentiment may be favored by parents concerned about the future of their
adolescent children.
In the year 2012, The American Academy of Child and Adolescent Psychiatry (AACAP)
published Best Principles for Integration of Child Psychiatry into the Pediatric Health Home, the
document that set out recommended guidelines for screening of mental health and substance use
disorders in the pediatric population (Martini et al., 2012). These guidelines recommend (1)
Screening for and early detection of mental/behavioral health problems, (2) Triage/referral to
appropriate adolescent behavioral health treatment & psychiatric consultations, (3) Care
coordination & collaboration with the health care team, mental health facilities, parents, family,
and child-serving agencies, (4)Access to child psychiatric specialty treatment for those with
moderate to severe psychiatric disorders, and (5) A mechanism to monitor outcomes at both the
individual case and delivery system level (Martini et al., 2012). These guidelines set an

optimistic tone on the possibility of improved screening and intervention rates for all aspects of
pediatric mental health and substance abuse. While the above guidelines are important, the first
two are especially significant in mitigating persisting problems in general pediatric mental
health. This is primarily because they involve the recognition of the problem (SUD and DD for
the purposes of this study) and the initiation of the therapeutic process towards successful
treatment. This study aims to determine the screening rates for SUD and DD and hypothesizes
that early detection and intervention will lead to lower prevalence rates.

Goals and Procedures
The clinic had four specific goals for implementing SUD and DD screening. The first
goal was to ensure smooth integration of SUD and DD screening among patients aged 12 – 21
years old who are current patients of the clinic. Based on the current demographic distribution of
the clinic’s patients, the target population comprises mostly adolescents from several counties in
Pacific Northwest (PNW). The implementation for PHQ-A was finalized prior to the beginning
of 2020 while the CRAFFT implementation was finalized in Mid-February 2020. Both
questionnaires automatically printed as part of the visit paperwork during the check in process.
The second goal was to administer and score each CRAFFT and PHQ-A form and enter
the information into each patient’s chart in the Electronic Health Record (EHR). Before the
implementation, all staff at the clinic were trained on scoring procedures for the CRAFFT and
PHQ-A forms and how to enter the scores appropriately into PCC, the EHR utilized at the clinic.
Each CRAFFT form was to receive a score between 0 – 6 and each PHQ-A form was to receive
a score between 0-27.

The third goal was to initiate interventions for patients who had a positive screen.
Depending on available resources, patients were to be referred for “in-house” counseling and/or
to other resources within the community. Pharmacologic interventions were also initiated if
individual providers determined their appropriateness. It is worth noting that the clinic retains an
in-house mental health counselor which some patients were referred to, based on the
appropriateness of their risk. The clinic also retains a consulting psychiatrist who rounds with all
providers on specific patients needing psychiatric consultation. The consulting psychiatrist is
available at the clinic every other Friday.
The final goal will be a follow-up for each patient who is screened. Follow-up involves
making a second appointment for a patient who initially screened positive. During the follow-up
appointment, the screening questionnaires are re-administered and scored to determine any
changes in the patient’s risk for SUD or DD. The clinic intends to administer both screenings at
every AWV and this will provide at least an annual follow-up for each patient. Generally, these
follow-up appointments will happen after this study has concluded. However, there were patients
that required sooner-than annual follow-up and this study was able to analyze data from patients
who attended follow up appointments during the study’s timeframe. Follow-up appointments are
important identifying and intervening in situations where a patient begin substance abuse or
develop depressive symptoms after prior screening negative. They also provide for monitoring of
changes in SUD and DD risk profiles as a measure of the effectiveness of CRAFFT and PHQ-A
screenings and interventions. Furthermore, continuity of screening will ensure that patients who
achieve the minimum inclusion age of twelve are screened early starting at the 12-year physical
exam. This will increase the likelihood of much earlier intervention as well as annual
opportunities for continued monitoring of risk and further interventions, if necessary.

Theoretical Framework
The nature of this study is best evaluated using two related theories: Theory of Reasoned
Actions (TRA) and the Theory of Planned behaviors (TPB). Primary data informs the
interrelatedness of these theories to SUD and DD in adolescents. The underlying assumptions are
that substance use is a consciously reasoned action by adolescents and that DD is as a result of
dissatisfaction with consciously sought social attention and fitting-in. One primary motivation of
adolescents is to achieve a certain social status within groupings. Hence the procurement and
utilization of drugs are with a particular motivation and dissatisfaction with social standing that
primarily predisposes DD. This theoretical framework is important because it assumes that just
as there is a predisposing motivation for SUD and DD , appropriate interventions can also
stimulate and propel a new motivation to improve health and social wellbeing by separating from
the harmful effects of drugs and by redefining personal perception of social acceptability. The
theory's utility provides an option to not challenge the intention of adolescents to feel better
about themselves. Rather, the goal is to pair qualifying patients with therapeutic resources and
treatment options that help them cope with prior social insecurities while also allowing patients
to intentionally refocus their motivation towards a self-purposed healthier and more socially
appropriate sense of personal fulfillment. This study builds on existing research data that has
documented substance abuse in adolescents but has left gaps in explaining whether preventative
interventions have any mitigating effect on the prevalence of SUD and DD. The framework of
the study will be heavily dependent on the collection and analysis of CRAFFT and PHQ-A data.
Analysis of the clinic’s screening, triage, and intervention processes assisted in evaluating the
sustainability of integrating CRAFFT and PHQ-A as part of the AWV.

Formative assessment was carried out during the study period and will continue even
after this study. It is a form of informative appraisal that is used to improve the processes of the
study towards predetermined goals (Leenknecht, & Prins, 2018). The clinic has an overall goal
of improving its screening rate and this study is setting the foundation for the eventual realization
of this goal. Formative assessment primarily serves to improve the quality of existing processes
by incorporating feedback and making adjustments that necessitate the achievement of the
predetermined objectives (Ranalli et al., 2017). The clinic intends to incorporate
recommendations derived from this study to improve its processes in a way that makes it more
likely to reach their screening and intervention goals. However, after the conclusion of this
study, the clinic will need to devise a process for ongoing evaluation on the impact of the
screenings, intervention, and triage processes.

Cultural consideration
In the context of depression and substance abuse, culture can only be defined with
cautious ambiguity. Culture is a multifaceted system of beliefs, values, and practices that
encompass many aspects of life without necessitating a relationship to ethnicity or race (Center
for Substance Abuse Treatment, 2014). There is no social mandate limiting alignment with
multiple cultures. For some, culture is ethnically based and for others, it is as personal a choice
as sexual orientation, religion, or even political beliefs. Given this complexity, this study
acknowledges the existence of diverse cultures within the study population but will remain
cautious to make assumptions on the present understanding of the cultural landscape as relates to
SUD and DD in adolescents. Although studies exist on the realms of cultural interrelatedness to
mental health and substance abuse, albeit a greater focus on the adult population, a proper

definition of culture remains elusive and risks improper assessment of the study population. This
study does not intend to evaluate the role of culture in SUD and DD prevalence, prevention, and
treatment among adolescents. This is with the consideration that culture can be important
especially in coping styles, social supports, stigma associated with diagnosis, treatment
preferences, or even patients’ willingness to participate in research studies. This study will
recognize the role of culture as a broad concept but will not attempt to define it.

Methods
Setting
This research study was conducted at a pediatric primary care clinic located in the PNW.
The clinic has a total of six physician providers and one nurse practitioner. Patients seen at the
clinic represent diverse racial, ethnic, and socioeconomic backgrounds from urban, suburban,
and rural settings as well as military and naval bases in the PNW. The clinic offers a variety of
services including routine healthcare and laboratory services.
Design
This is a quality improvement project focusing on screening for SUD and DD in the
pediatric primary care setting. In February 2020, the clinic finalized implementation of evidencebased screening tools for SUD and DD among adolescents. The CRAFFT tool was chosen to
screen for SUD while PHQ-A was chosen to screen for DD. The clinic's primary goal for
implementing the two tools was for early identification of SUD and DD among the patient
population and to connect them with appropriate community resources and interventions.
Secondary goals were to identify any correlations between SUD and DD within the patient
population and to identify risk factors for either or both SUD and DD associated with geographic

areas of residence, age, gender, or socioeconomic status. This study involved a report from the
clinic’s EHR for frequencies of patients who completed the CRAFFT and PHQ-A tools, their
demographic and insurance information as well as their CRAFFT and PHQ-A scores and referral
information.

Screening tools review
CRAFFT Substance abuse/dependence screening questionnaire (Appendix A)
The CRAFFT (Car, Relax, Alone, Friends/Family, Forget, Trouble) assessment tool
(Part, 2009; www.crafft.org) was developed to identify substance use, risk of substance
dependence, and the presence of SUD among adolescents and teenagers aged 12 – 21 years old.
It is a comprehensive assessment that evaluates various aspects of adolescent lifestyles that may
predispose the use of substances (Bivin & Riaz, 2017). The CRAFFT tool has been shown to
have high sensitivity and internal consistency (Pilowsky & Wu, 2013; Smith et al, 2017; Carney
et al., 2016). CRAFFT is a validated screening tool for risk of SUD in the pediatric population
(Mitchell et al., 2014; Bagley et al., 2016). Its utility in screening for SUD, though not
diagnostic, is endorsed by DSM-V and recommended by the AAP’s Committee on Substance
Abuse (Bagley et al., 2017; Shenoi et al, 2019). CRAFFT provides pediatric providers a
practical methodology to quickly identify adolescent patients in need of more comprehensive
assessments and referrals to substance abuse treatment specialists (Crouch, 2019). Although the
CRAFFT questionnaire is easy to administer to patients, it has only been sparingly utilized in
pediatric practices, as is the case with other screening tools for all aspects of mental health. The
CRAFFT questionnaire was selected for this study because it was primarily developed for the
age group within the study inclusion criteria. The language is simplistic in accounts for the

education and literacy level of adolescent patients. The administration process is quick, and most
patients can complete the questionnaire in less than five minutes, which is lesser than the average
clinic waiting time between check-in and interaction with provider. Because the question
involves only nine questions, the scoring process is also easy and quick, hence enabling
providers to integrate the administration process within the timeframe of a clinic visit. Even for
providers that lack familiarity and training on substance abuse screening tools, the CRAFFT
questionnaire utilizes statements that are more relatable to patient’s life in a way that providers
can make sense of. For this study, the intention of utilizing the CRAFFT questionnaire was for
quick and early identification of SUD and for clinic providers to identify which patients needed
interventions against SUD. It is worth noting that the CRAFFT questionnaire is not a diagnostic
tool and only evaluates for the risk of SUD.
Previous studies have consistently shown that a score of two or more out of 6 is
consistent with a risk greater than 50% for substance dependence (Knight et al., 1999; Knight et
al., 2002). This study follows these findings and classifies patients scoring two or above as
having a positive screen and hence in need of intervention. Although the writer acknowledges
ongoing debates about the distinction between substance use versus substance dependence, this
study does not attempt to elaborate on this debate but lumps all positive screens as a singular
problem. The extent to which the CRAFFT tool is used in primary care is unclear. However, just
like with PHQ-A, this tool can be a vital component of pediatric health maintenance when SUD
incidences are detected early, and interventions initiated promptly. This study supports the notion
of integrating CRAFFT as part of routine health maintenance in adolescents.
The CRAFFT screening tool is a 9-item “Yes/No” questionnaire with two parts. Part A
has 3 questions that are not scored. A "Yes" to any of the 3 questions requires the patient to

complete all questions in Part B. A "No" to all questions in Part A requires that the patient
complete only the first question in part B. Part B has six questions and a “Yes” to two or more
questions constitutes a positive screen for SUD.

PHQ-A (Patient Health Questionnaire Modified for Adolescents)(Appendix B)
The PHQ-A screening tool is a validated version of the adult PHQ-9 and has been used
extensively in pediatric psychiatry and primary care to identify pediatric patients with depression
(Burdzovic et al., 2017; Heim et al., 2008; Pillemer et al., 2010). It is designed to be used by
clinicians and psychiatrists to diagnose or determine the risk of depression among adolescents.
This tool was developed by the American Psychiatric Association (APA) as part of its Diagnostic
and Statistical Manual of mental disorders (DSM- Currently at version V) (Cannon et al., 2019;
Amtmann et al., 2014; Kocaleventet al., 2013). The purpose of the PHQ-A is to provide
diagnostic information for depression in pediatric patients. The extent of utility in pediatric
primary care is not known. However, judging by existing treatment gaps for depressive
disorders and significant delays in psychiatric treatment, it is plausibly the case that this tool is
underutilized (Gaínza-Lein et al., 2018). This is despite research evidence that adolescents are
more prone to depression due to physical, emotional, and hormonal changes as well as factors
such as bereavement, neglect, substance abuse, mental abuse, physical abuse, sexual abuse, and
unequal parental treatment of siblings (Heim et al., 2008; Pillemer, et al., 2010). In this study, the
author intends to evaluate whether integrating DD screening in pediatric primary care using
PHQ-A is effective in the identification, intervention, and triage of DD in the study population.
The author also intends to evaluate whether integrating it as part of AWV is sustainable.

The PHQ-A screening tool has two sections. The first section evaluates depressive
symptoms over the last two weeks and has 9 questions each with scores ranging from 0 to 3. The
maximum score for this section is 27. A score of 10 and above is considered a positive screen for
at least moderate DD. For this study, the second section of the PHQ-A was not utilized. The
author, however, recognize that the unincluded section can yield vital information that can
further inform the understanding of DD in adolescents.

Sample
The study population was adolescents and teenagers aged 12-21 years old. The inclusion
criteria were patients who arrived at the clinic for AWV between March 1, 2020, to Dec 31,
2020. Exclusion criteria included patients under the age of 12 years or those older than 21 years
and patients seen at the clinic for reasons other than AWV.

Screening tools administration procedures
During the check-in process at the front office, a PHQ-A questionnaire and a CRAFFT
questionnaire were provided to each patient in the inclusion criteria as part of the visit
paperwork. Each patient was notified of the option to not participate and verbal informed consent
was obtained for those who chose to go forward with the screening. Those patients who did not
opt-out were asked to wait to complete the questionnaires until when called to the exam room.
When the patient arrived in the exam room, accompanying parents/guardians were instructed to
remain outside the room while the patient completed both questionnaires confidentially. The
forms were then scored, either by a Medical Assistant (MA) or a nurse and recorded in the EHR.
The provider then reviewed both the PHQ-A and CRAFFT forms with the patient. In the case of

positive screens, the provider discussed available treatment, therapy, and referral options.
Patients were allowed to call parent/guardian to room, if they chose, once the questionnaires
were completed and discussed with the patient. Patients could consult parents/guardians about
possible intervention if they chose to. It is worth noting that the CRAFFT and PHQ-A screenings
were conducted in tandem with other aspects of AWV (Appendix C)

Data collection
Data was obtained through a report inquiry from the clinic’s EHR and stored in Microsoft
excel format in the clinic's computer. In total, 1417 charts matching the inclusion criteria were
retrieved and reviewed. The following data was collected: - age, gender, race, geographic area of
residence (Zip code), and insurance information. For each of the included patients, PHQ-A and
CRAFFT information was collected.

Data privacy and de-identification process
All charts retrieved and reviewed were accessed only at the clinic and only using clinic
computers. Data was extracted in the form of a "batch report" from the clinic’s EHR and stored
only at the clinic computers in the form of Excel workbooks. Data stored in Excel workbooks
were de-identified to exclude patient names, medical record number, social security numbers,
date of birth, full address, or exact date of visit. All Excel analysis was conducted at the clinic
using the clinic's computers. Only fully de-identified aggregate data was stored on the PI’s
computer and used for SPSS (Statistical Package for Social Science) analysis through Seattle
University Library.

Measures
Frequencies were computed for the positive and negative screens for both CRAFFT and
PHQ-A screening tools. The author then computed the frequencies of positive and negative
screens for each of the represented ages, races, gender, and insurance type. Computing the
frequencies per zip code were intended to identify whether cases of SUD and DD had geographic
concentrations. Frequencies per gender and race were to identify if there were any gender or
racial correlations for either SUD or DD while computing the same frequencies for insurance
type was to provide some insight on socioeconomic association with either SUD or DD.
Measures of geographic areas of residence, gender, race, and socioeconomic status were also
utilized to determine if there were any disparities in the screening, intervention, and
triage/referral rates. For this study, the assumption is that patients with Provider One and Molina
Medicaid insurance policies are of lower socioeconomic status. The writer also computed the
frequencies of the overall qualifying patient (all patients 12-21 years arriving for wellness visit)
to be able to compute the screening rates for each tool.
Consistent with established guidelines, CRAFFT scores of 2-6 were considered a positive
test, indicating a greater than 50% risk of substance dependence and hence need for intervention.
For DD, the study also utilized established guidelines of scores 10/27 or more on the PHQ-A,
consistent with moderate depression, as a positive screen requiring intervention. Since the
CRAFFT and PHQ-A were administered to each patient at the same time, a patient could qualify
for intervention based on either tools or both. This is because of existing compelling evidence of
cooccurrence between SUD and DD as well as the knowledge that available community
resources catered for patients with either or both conditions. The clinic intended to intervene for
all patients screened positive . This could be through pharmacologic intervention prescribed by

the provider, referral to the clinic’s in-house mental health therapist/counselor, referral to clinic’s
consulting psychiatrist or referral to community mental health and substance use resources.

Data Analysis
Microsoft Excel was used to group participants' data into demographic categories (age,
gender, zip code, household types) as well as socioeconomic classes (SEC) based on insurance
type (Provider One and Molina Medicaid is equal low SEC; private or employer-based insurance
is equal to high SEC). It was also used to calculate the rates of SUD and DD in each
demographic and SEC category.
SPSS software and Microsoft Excel were utilized to derive correlations between SUD
and DD in the study population and to calculate statistical differences in the rates of SUD and
DD between demographic and SEC categories. Both SPSS and Microsoft Excel were also
utilized to perform regression analyses to identify the correlation between demographic and SEC
categories with occurrences of either or both SUD and DD.

Results
Patient population and screening rates
Between the period of March 1, 2020 and December 31, 2020, 1419 patients met the
inclusion criteria for this study. Two patients were excluded from the analysis because their
charts had incomplete demographic information. There were 1347 patients who completed the
PHQ-A questionnaire, representing a screening rate of 95%, while 1219 patients completed the
CRAFFT questionnaire representing a screening rate of 86%. The PHQ screening rates for males
(96% or 637/666 patients) and females (95% or 710/751) were similar. The CRAFFT screening

rates for males was 88% (585/666), which was four percentage points higher than the female rate
of 84% (634/751). There were 1185 patients completed both questionnaires, and this
approximated to 84% screening rate. Most patients stated English as their preferred primary
language (92.4%) and Spanish was the second most preferred language (6.8%). A small minority
of patients (0.8%) did not have a preferred primary language, or their preferred language
represented < 0.1%. In terms of patient ages, more than 85% of patients were between the ages
12 – 18 years old. The screening rates for both SUD and DD were higher than 80% across all
represented age groups with the exemptions of SUD screening for 18-year-olds and 19-year-olds
(79% and 60%) and DD screening for 20- year-olds (75%).

Figure 1

Overall study population and screening rates. Both means that patient completed both PHQ-A
and CRAFFT questionnaires.

The racial composition of the study population was diverse although Caucasians were
overrepresented (75%). Other races were mixed races (4%), African American (3%), Asian
(2%), American Indian or Alaskan Native (1%), Native Hawaiian or Pacific Islanders (1%),
while 14% of patients did not prefer to be identified with any race. With the exemptions of SUD

screening for mixed races (78%), both the SUD and DD screening rates were greater than 80%
across all races.
There were 42 zip codes represented within the study population mostly within a 50 miles
radius from the clinic. There were two zip codes were from outside State. These were associated
with military families from local bases. Approximately 77% of patients were from the zip codes
immediately surrounding the clinic. The screening rates in each represented zip codes were
greater than 80%.
In evaluating the patient population by insurance types, 75% of patients had private
insurance or insurance through an employer, 23% had Medicaid insurance (Provider One or
Molina Medicaid), and 2% did not have insurance and hence were billed as private payers. For
this study, patients with Medicaid insurance were presumed to be less thriving economically than
those with private or employer-sponsored insurance. Because the author did not evaluate the
circumstances relating to the lack of insurance, this study did not make any economic
assumptions for those billed privately. The screening rates were similar (90 – 95%) across all
insurance types.
There were 249 patients who qualified for intervention based on either a CRAFFT score
of two or higher or a PHQ-A score of 10 or higher. Of these, 59 patients (23.6%) received some
form of intervention. The interventions utilized for these patients were pharmacologic (32%, n
=32), counselling (19%, n = 11), referral to Psychiatrist (5%, n = 4), and follow up (44%, n =
26). Follow-up meant that the patient attended a second appointment at the clinic in which
screening forms were readministered. During the study period, the only follow up appointments
identified were based on positive screens on PHQ-A only.

Of the 189 patients who screened positive on the PHQ-A, 26 of them had a follow-up
appointment scheduled to re-evaluate their DD symptoms. For this set of patients, the average
PHQ-A score for the initial visit was 16 while the average at follow-up visits was 12, a
statistically lower mean score. Although the PI is unaware of the providers’ reasoning behind
following up with these specific patients compared to others with similar scores, the lower PHQA average for follow-up visits did yield the prospect that follow-up alone - or in combination
with other interventions – may have a therapeutic impact.

Figure 2

The percentage composition of the study population gender, primary language, age, and
gender

Figure 3

CRAFFT and PHQ-A Screening rates in the study population by categorization of race,
primary language, age, and race

Figure 4

Study group categorization by insurance type.

Findings
Data from this study showed that the clinic's screening rates were six-times higher than
the national average for SUD (86% vs 14%) and three-times higher for DD (95% vs 34%). This
is consistent with the clinic's goal of improving their screening rates to as close to 100% as
possible. Both SUD and DD risk were remarkably similar between all genders. The proportion of
CRAFFT positive cases was 49.6% for males and 47.3% for females. The PHQ-A positive cases
were similar between males and females (14.4% and 13.7% respectively). When evaluating the
positive rates based on the patient preferred primary language, data showed that patients who
listed English as a preferred language had a higher risk for both SUD and DD. CRAFFT positive
rates were 4.9% for English speaking patients 3.6% for Spanish speaking patients. For PHQ-A,

positive rate for English speaking patients was 14% compared to 10% for Spanish speaking
patients. This was an important notation considering that both the PHQ-A and CRAFFT forms
were administered in English. The author was uncertain whether the low positive rates for
Spanish-speaking patients may have been confounded by the language to which the forms were
administered. This may require further evaluation contrasting with a similar population utilizing
the Spanish versions of both forms. It should be noted that both the PHQ-A and CRAFFT forms
are available in Spanish and they have been validated to have similar sensitivity and selectivity
and hence reliable for the Spanish-speaking population. For this study, the author did not
evaluate this topic further other than noting the low scores for Spanish-speaking patients.
In terms of race, the study population tended to have lower scores compared to the
national average. The author’s data indicated that patients of mixed races had the highest risk of
substance use disorder (13%), followed by African Americans (6.2%) and whites (4.6%) which
is consistent with national data for these races. In the data, there was no identification of any
CRAFFT positive screens For Native American or Alaskan natives, native Hawaiians, and
Pacific Islanders, and Asians. This is inconsistent with the national data that has shown that those
of American-Indian background has the highest risk of substance use disorder in adolescence.
However, the author recognizes that the study sample was much smaller and more
geographically concentrated than the national sample. The writer also notes that the recruitment
procedure of focusing on only one primary care clinic may have limited the ability to have a
more representative sample.

Table 1
Race

National Ave. Study Pop.

American Indian or Alaskan Native

17.6%

0%

Asian

4.5%

0%

Black/African American

13.1%

6.2%

Mixed Races

17.1%

13.0%

Native Hawaiian/Pacific Islanded

10.4%

0%

White

11.6%

4.6%

SUD risk in study population compared to national average.
(National data retrieved from: Patnode et al., 2020)

The overall risk of DD within the study population (14%) was generally similar to the
national average (13.3%). The author also found a consistency in the risk profile for patients of
mixed races who had an average risk of 18% in the study population compared to 16.9%
nationally. The rate for the Caucasian population was also similar at 15% for the study
population and 14% for the national average. However, the study findings were inconsistent for
American Indians/Alaskan natives whose national risk is at 16.3% compared to the study
population of 0, Asians with the national average of 11.3% compared to 3% in the study

population and African Americans whose national average is lower at 9.5% compared to 21% in
the study population. Like the findings for SUD screening, the limitations specific to the study
population and the recruitment procedures could have a confounding effect on the findings of
this study.
Table 2
Race

National Ave

Study Pop

American Indian or Alaskan Native

16.3%

0%

Asian

11.3%

3%

Black/African-American

9.5%

21%

Mixed Races

16.9%

18%

Native Hawaiian/Pacific Islanded
White

14.0%

7%
15%

Comparison between the DD rates in the study population compared to the NIH national data
for adolescents (Nation data available retrieved from: National Institute of Mental Health,
2019)

In general, the author found that the risk of both SUD and DD increased with age.
Consistent with prior research studies and CDC data, the author found that patients in the
youngest age group in the study population tended to have lower scores on both screening tools.

Figure 5

Rates of Positive screens by age
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Rates of CRAFFT positive and DD Positive screenings by age in the study population

One of the key findings of this study was that there is a general correlation between SUD
and DD. For those patients who screened positive on the CRAFFT questionnaire, their average
PHQ scores were notably higher compared to those of patients who scored negative on the
CRAFFT questionnaire. Similarly, for patients who had a score of 10 or higher on the PHQ
questionnaire, the average CRAFFT scores were higher than those that had scored less than 10
on the PHQ-A questionnaire.

Figure 6

Left graph shows the mean PHQ-A scores for patients who had negative screens and those
with CRAFFT screens of 2-3 and >4, Right graph shows the mean CRAFFT scores for
patients in the study population without depression and those with moderate, severe, and very
severe depression.

The intervention rate for the clinic was found to be 24% (59/248) based on both
screening tools. This represents an intervention rate that is double the national intervention
average of 11% for SUD but less than half the national DD intervention rate of 56%. This
indicates the clinic is making some ground in intervening against SUD but at the same time
falling short for DD.
Conclusion and Discussion
Several conclusions could be derived from the data obtained from this study. The clinic's
overall screening practices were better compared to nationally reported data on pediatric
practices screening for SUD and DD. The clinic generally maintained an average screening rate
above 80% for most of the measures in this study. The general screening practices for the clinic
are mostly equitable across genders, races, and other demographic criteria as there were no

significant noted in the modalities of screening. However, the screening rates for patients of
mixed races were generally lower at 75% and this may be problematic considering that the study
data and nationally reported data indicate that mixed-race background is among the most positive
correlated racial factor for the risk of both SUD and DD.
Based on the study data analysis it appeared that the greatest risk factors for SUD and DD
were older age and mixed-race background. The author also noted that patients who identified
English as the primary language had generally higher scores for both CRAFFT and PHQ-A. At
this time, the author is unable to make plausible conclusions on the role of language or culture in
explaining the lower scores for Spanish-speaking patients. The author does recognize that both
CRAFFT and PHQ-A screening tools are available in Spanish and further studies may be needed
to evaluate whether scores derived from the Spanish version would be any different or similar to
those derived from this study.
The author concludes that integrating SUD and DD screening in pediatric primary care is
possible and sustainable. During the study period, the clinic was able to sustain an overall
screening rate above 80% without significant variation in other aspects of AWV. Notably, the
clinic provider reported that the average length of AWV did not change significantly after the
integration of CRAFFT and PHQ-A screenings. While this may be credited to patients
completing the two-screening questionnaires within the 10-15 minutes average waiting time
from check in to provider seeing patient, it was unlikely that other aspects of patient care were
compromised. Providers were still able to see the same number of patients during the day and
none of the providers stated concerns about their ability to deliver quality care during the AWV.
Most clinic staff members expressed confidence in their ability to score the PHQ-A and
CRAFFT forms and to record the scores accurately in the EHR. There was consensus among the

providers on what constituted a positive and a negative screen, as well as their ability to
recommend interventions. Considering that the staff training was very short, the author
concluded that the simplicity of the two screening forms allows for integration into pediatric
primary care without lengthy and expensive training. This is an important notation given the role
of screening in the overall high prevalence of SUD and DD.
This study took place during the COVID-10 pandemic and lock-down measures instituted
by state and local governments impacted the operation of the clinic and community mental health
resources. The author notes that these measures affected the ability of the clinic providers to find
ready community services to refer patients to. The author concludes that the low intervention
rates, despite the high screening rates, may not have been solely due to the clinic practices. The
extremely limited mental and substance abuse resources during the study period dictated a need
to triage more severe cases. Furthermore, the backlogs resulting from the pandemic closures of
many non-hospital healthcare organizations meant that by the time this study concluded, most of
the patients in the study population were still without intervention. For this study, only
interventions that were successfully processed were included in the analysis and this may have
excluded referrals recommended by the providers but not successfully processed due to
unavailability of appointments at community mental health and substance abuse outpatient
resources.
Based on the analysis of the data, the author notes that the clinic’s generally higher
screening rates are encouraging in setting a more optimistic prospect of increased screening and
intervention. Even though there were hindrances related to the COVID-19 pandemic, the impact
of the clinic’s screening initiative cannot be underestimated. This study alone yielded 248
positive screenings for both SUD and DD that might otherwise have been missed in the absence

of the clinic’s initiative. As the clinic continues to evaluate and improve on its mental health
processes, it can be anticipated that sustained screening and improvements in the intervention
and triage rates will positively impact this population. Because the data analysis indicates that
some risk factor for SUD and DD in the study population (mixed age, older adolescents, and
SUD-DD cooccurrence) mirrors a CDC national survey, the clinic providers understand that their
screening model can be generalizable to the adolescent population in the United States. The
challenge identified in this study are not unique to the study population and hence the clinic’s
initiative may model a future screening and intervention approach with a national impact. And
while the intervention rates for DD was below the national average, the author want to point out
that the purpose of the study was to recognize and correct any existing gaps within the clinic
processes. Therefore, it is more likely that the clinic’s intervention rate will continue to rise and
may even surpass the national average soon.

Recommendations based on the findings of this study.
First, the author would like to applaud the initiative of the clinic in recognizing persisting
problems in the general mental health sector. The implementation of the CRAFFT and PHQ-A
screening will be vital in mitigating the prevalence of SUD and DD within the clinic’s
population. While individual benefits to patients will vary, the scope of the clinic’s initiative will
be a more well-rounded approach that will encompass the entirety of the patient’s health
physically and psychologically. The recommendations in this segment are with the recognition
that the COVID-19 pandemic and lock-down measures may have confounded the study findings.
The following recommendations have the most contributory benefit to SUD and DD screening in
the adolescent population.

Continued screening
The number of positive cases detected during the study period supports the need for
continued screening in this age group. Given that there were identifiable risk factors within this
population, screening procedures may also need to be refined to ensure fewer missed cases for
patients in high-risk groups. For example, in the data, the mixed races racial group had a
relatively lower CRAFFT screening rate (75% compared to an overall CRAFFT screening of
86%) even though this group has the highest risk in the study population (13%) and nationally
(17.1%). The author recommends that pediatric providers initiate or continue screening
procedures in the general adolescent population.

Increased use of the in-house mental counselor and consulting psychiatrist
Of all the patients who received interventions, only 19% were referred to
counseling/mental health therapist (including the in-house counselor). This resource has the
greatest potential if higher intervention rates are to be achieved. Since the counselor works from
within the clinic building, the triage process may be logistically simpler and there may be an
opportunity for prompt intervention where same-day referrals are possible. Some patients may
also feel more comfortable receiving intervention within an environment they are already
familiar with. The same recommendation goes for the consulting psychiatrist who can see
patients within the clinic environment at least weekly. Whenever possible, the author
recommends that pediatric practices retain or contract a mental health/substance abuse counsellor
in order to minimize logistical gaps that either delay or hinder SUD and DD intervention
processes.

Continued learning of provider
Because of the generally limited mental health resources, there may be a need for
pediatric primary care clinics to increase their self-reliance in the management of pediatric SUD
and DD. The author recommends that pediatric PCPs maintain a comprehensive knowledge of
the most current SUD and DD management guidelines because they may be the only resource
available for patients. This is with the consideration that community mental health facilities are
presently dealing with significant backlogs and their services are historically scarce even during
non-pandemic times.

More follow-ups
The study analysis indicated that the average PHQ-A score for follow-up appointments
was statistically lower compared to the average of the initial scores. This vital finding indicates
that even in the absence of other interventions, following up with patients could have therapeutic
potential. The author recommends that pediatric primary care clinics maintain plans to follow up
with all patients who screen positive on either questionnaire regardless of whether they have
been paired with other community mental and substance abuse resources. This will serve the
purpose of evaluating the effectiveness of those community resources and more importantly
providing an opportunity for PCPs to intervene for those patients who have yet to receive any
intervention.

Continued monitoring and evaluation of screening and intervention processes
Considering the statistics derived from this study, and also the National Statistics as
regards SUD and DD, the need for at least an annual screening for both of these conditions is

very important. Continued screening will have a profound effect on the adolescent population in
terms of clinical outcomes as well as in promoting social acceptability, family unity, and
personal self-worth. The author recommends continued of screening processes in order to
determine their effectiveness in mitigating the incidences and prevalence of SUD and DD. It is
likely that this will fill some of the gaps that have long existed in the general mental health sector
at least for the benefit of the adolescent population.

Implications for practice
The most recent data show that high number of adolescents are using substances. At the
same time, the depression rates have been increasing in the general population and more
significantly in adolescents. Although both federal and state governments have continued to
implement more restrictive measures that make it difficult for the acquisition of controlled or
illegal substances, more states continue to either legalize marijuana or relax enforcement
ordinances. This has presented a notable trend of spiking marijuana rates even as the rate of other
drugs mildly decline or remain steady. There is no identified general health benefit from
marijuana and the author uncertain of the political reasonings behind these marijuana legalization
measures. What is clear is that the general health impact has been detrimental to adolescent
health. Although adolescents cannot legally acquire marijuana, its increased supply within the
general population has eased the ability of adolescents to acquire and use it (Turel, 2020; Koval
et al, 2019; Brooks-Russel et al., 2018; Salas-Wright et al., 2017; Harpin et al., 2017).
The leading causes of death among young people are associated with SUD and DD. Injuries
(accidental or intentional) are the leading cause of death in adolescents and this is strongly
correlated with both SUD and DD. It is notable suicide rates have been increasing at nearly

identical pace with SUD and DD (Curtin & Heron, 2019). Given that SUD and DD can
predispose suicide, early screening and intervention may equate to saving adolescent lives. The
rates of teenage deaths from Motor Vehicle Accidents (MVA) have been on the rise and there is
a remarkable correlation especially to SUD with impaired driving noted as one of the leading
causes of MVA in adolescents (Banz et al., 2019). At the same time, the rates of poisoning
deaths have also remained significant among adolescents, bear in mind that some forms of
overdose from drugs can be classified as poisoning (Cunningham et al., 2018). Rates of
homicidal deaths also remain steadily high among adolescents and some of these deaths may
happen in the process of acquiring drugs or due to gang activities involving drugs (Brookman et
al., 2017). Given these statistics, the case for continued screening for SUD and DD has an even
greater community impact beyond the clinic’s object to improve health outcome. The
interventions of this clinic may save lives.

Figure 7

Fig 12: Current trends in national suicide rates for ages 10 – 19 years old (Curtin &
Heron, 2019)

As noted earlier, most SUD referrals are channeled from the justice system. This means
that a significant proportion of adolescents are in some form of legal trouble. The implications of

adolescents’ involvement with the justice system can have lifelong consequences. Most
employers require some form of background check. Therefore, the future employability of
adolescents with SUD could be in jeopardy. Low employment prospects in adulthood can lead to
many undesirable social and economic situations some of which could predispose SUD and DD
in adulthood and other illegal activities such as burglary, gang activity, suicide, and even
homicide. Therefore, intervening during adolescence is critically important because it provides
the greatest potential to shape the future health, social, and economic wellbeing of patients
through adolescence and into adulthood.

Limitations
This study happened during the COVID-19 pandemic. In the same month that the study
commenced the state government instituted restrictive measures limiting all forms of person-toperson contact. Many non-hospital health care organizations, including the clinic where this
study was conducted and community mental health and substance abuse facilities, significantly
limited their operations. This led to a significant decline of non-acute visits, including AWV,
especially in the early days of the pandemic. In this way, our study sample was likely smaller
than it would have been had this been a non-pandemic period. Although we cannot speculate on
how this could have affected out findings, we can presume that a larger patient sample has
greater potential to be more representative of the adolescent population.
We recognize that most outpatient mental health institutions either closed or limited their
operations due to COVID-19 measures implemented in this state. This severely limited the
number of resources available for the clinic providers to refer patients to. And while the clinic
maintained generally highly screening rates, community mental health resources were extremely

scarce during the study period. Therefore, the intervention rate would likely have been higher
had these community mental health resources or facilities been operating at their normal patient
capacity. Even at the time when this study concluded, there were still significant backlogs for
mental health and substance abuse outpatient services as these facilities struggled to catch up.
Notably, these backlogs only exacerbate the care gaps on an already thinly stretched mental
health sector.
As the clinic adjusted its operations in the aftermath of pandemic-related governmentmandated lockdown measures, the clinic instituted measures to limit the number of staff
members simultaneously present at the clinic due to the recommendation of CDC and state
government. Some of the clinic services, including mental health counseling were temporarily
halted as arrangements were made to transition to virtual care. This established a time-gap during
which the in-house mental health counselor was not available to intervene for positive SUD and
DD. This also constrained the intervention rates as other community resources were already
scares.
There were technical challenges during the process of integrating the screenings as part
of AWV. These mainly affected the CRAFFT screening for SUD. The PHQ-A forms were
integrated much earlier, and this allowed for more time to tweak any technical challenges.
However, CRAFFT forms integration was finalized in February 2020, the month immediately
prior to the start of the study. There were incidences where the CRAFFT forms were not printing
properly or not printing at all as part of the AWV paperwork package. Hence, the lower rates for
SUD screening compared to DD may have been due to these logistical challenges. It is worth
noting that both CRAFFT and PHQ-A are printed together and there should be equal
opportunities to administer both to every qualifying patient.

Dissemination of Results
The clinic where the study was conducted is noted as the primary stakeholder and this
study is designed with the intent of improving screening and intervention rates for their patients.
However, the results of the study may be generalizable with the potential of benefiting pediatric
practices locally and nationally. To aid in the dissemination of the study findings, the study will
be published in journals of Advanced Practice Nursing and/or Family Medicine journals making
this information widely available to primary care clinicians and researchers. This will also
provide room for critiques that may provide further helpful information that can be integrated
into pediatric mental health practices and processes.
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Appendix
Appendix A: The CRAFFT assessment tool (Knight et al., 1999; Knight et al., 2002)

Appendix B: The PHQ-A depression Screening form

Appendix C: The workflow of the clinic during a normal visit. The red font indicates
where CRAFFT and PHQ-A screening have been integrated into the visit workflow

